Skip to main content

Bruker Corp(BRKR-Q)

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Bruker Corporation to Present at Investor Conferences

Business Wire - Wed Feb 22, 2023

Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences:

Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference in New York City

Thursday, March 2, 2023, at 9:30 a.m. Eastern Time

Cowen 43rd Annual Health Care Conference in Boston, MA

Monday, March 6, 2023, at 2:10 p.m. Eastern Time

Live audiovisual webcasts of the presentations will be available on the Investor Relations section of the Company's website at Replays of the presentations will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the events and will be available for 90 days following the presentations.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life-science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial research, semiconductor metrology and cleantech applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit:

Provided Content: Content provided by Business Wire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe